Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Accumulated Depreciation & Amortization (2016 - 2026)

Cytosorbents filings provide 15 years of Accumulated Depreciation & Amortization readings, the most recent being $5.1 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 21.77% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 21.77% increase, with the full-year FY2025 number at $5.1 million, up 21.77% from a year prior.
  • Accumulated Depreciation & Amortization hit $5.1 million in Q4 2025 for Cytosorbents, down from $5.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $5.3 million in Q3 2025 to a low of $1.9 million in Q4 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $4.7 million (2021), compared with a mean of $4.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 60.16% in 2022 and later skyrocketed 60.07% in 2023.
  • Cytosorbents' Accumulated Depreciation & Amortization stood at $4.8 million in 2021, then plummeted by 60.16% to $1.9 million in 2022, then skyrocketed by 60.07% to $3.0 million in 2023, then surged by 39.19% to $4.2 million in 2024, then increased by 21.77% to $5.1 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $5.1 million (Q4 2025), $5.3 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.